The cell cycle represents a series of tightly integrated events that allow the cell to grow and
proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), …

… Obesity, and, in particular, central (visceral) obesity, is the second strongest risk factor for
Barrett oesophagus and OAC (OR for individuals with a high body mass index (BMI): 2.69 (95% …

The concept of combining chemotherapeutic agents to increase cytotoxic efficacy has
evolved greatly over the past several years. The rationale for combination chemotherapy has …

Background First-line therapy for advanced oesophageal cancer is currently limited to
fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity …

At Berkeley, we are developing TelegraphCQ [1, 2], a dataflow system for processing
continuous queries over data streams. TelegraphCQ is based on a novel, highly-adaptive …

… Dr Shah has received institutional research funding from Merck, Roche, and Boston Biomedical.
Dr Metges has received honoraria from Eli Lilly, Sanofi, Novartis, and Merck. Dr Garrido …

… Shah et al 20 showed that bevacizumab plus platinum-containing chemotherapy had
promising efficacy in patients with metastatic gastric/gastroesophageal junction adenocarcinoma (…

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric …

Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.2),
has shown efficacy in patients with CLDN18.2-positive, human epidermal growth factor …

Purpose Bevacizumab improves survival in several solid tumor malignancies when combined
with chemotherapy. We evaluated the efficacy and safety of the addition of bevacizumab …